Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 88Lung Neoplasms 70Small Cell Lung Carcinoma 11Pleural Effusion, Malignant 9Melanoma 7Ovarian Neoplasms 6NSCLC 6Pleural Effusion 5Neoplasms 5Head and Neck Neoplasms 5Stomach Neoplasms 4Mesothelioma 4Lung Diseases 4Carcinoma, Renal Cell 4Carcinoma 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Thoracic Neoplasms 3Pneumothorax 3Pleural Neoplasms 3Pancreatic Neoplasms 3Non-Squamous Non-Small Cell Lung Cancer 3Neoplasm Metastasis 3Liver Neoplasms 3Kidney Neoplasms 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Brain Neoplasms 3Venous Thromboembolism 2Urinary Bladder Neoplasms 2

Interventions

durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Unresectable Non-small Cell Lung Cancer (NSCLC) × Thoracic × Clear all
NCT04416633 2024-11-08

Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC

AstraZeneca

Phase 4 Completed
100 enrolled 11 charts
Thoracic

Unresectable Non-small Cell Lung Cancer (NSCLC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡